The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, pilot study evaluating the efficacy of tildrakizumab on the treatment
of bullous pemphigoid (BP) in eligible patients (see detailed study protocol). Three total
doses of tildrakizumab 100mg will be administered at Weeks 0, 4, 16 a total of 16 weeks of
treatment by the study staff to patients with bullous pemphigoid. The patients will be
followed for a total of 24 weeks.